.png){kind=icon}
.png){kind=icon}
Return
Molecular Tumor Board–Guided Osimertinib Therapy in EGFR L858R/Q701L–Mutant Lung Adenocarcinoma Supported by Functional Validation
.png){kind=icon}
OA
AI
C
M
F
B
N
S
A
M
S
C
M
DOI：10.1093/oncolo/oyag242.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Rare or compound EGFR variants in non–small cell lung cancer (NSCLC) can create substantial therapeutic uncertainty, particularly when accompanied by additional co-alterations with potential resistance implications. In such settings, molecular tumor boards (MTBs) may integrate genomic, functional, and clinical data to guide treatment selection.
Journal
T
IF:
0
Papers:
188
Citations:
0
Organization
Cited Papers